Allogenic BM-MSCs

Developed for: lumbar disk degenerative disorder
Investigated by: APHP · BG Klinikum Bergmannstrost, Halle, Germany · Campus-Bio-Medico University · Centre National de la Recherche Scientifique, France · Citospin · Département de l'information médicale, CHU de Montpellier
+11 more
· European Clinical Research Infrastructure Network · Institut de Terapia Regenerativa Tissular · Interdisziplinäres Zentrum Klinische Studien (IZKS) · Nantes University Hospital · National University of Ireland, Galway, Ireland · Rennes University Hospital · Univercell-Biosolutions S.A.S · University Hospital, Montpellier · University of Navarra · University of Valladolid · Université Montpellier

today NCT03737461 · Ph 2/3

20192020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2/3	NCT03737461	Feb 2019 → May 2022 overdue	lumbar disk degenerative disorder	University Hospital, Montpellier	Active not recruiting	Missed primary

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Allogenic BM-MSCs	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03737461 ↗
Known as	allogeneic BM-MSC	“Participants were randomised in a prospective, double-blind, controlled study to receive either sham injection or intradiscal injection of 20 million allogeneic BM-MSC, between...” PMID 39393844 ↗ Oct 2024
Known as	allogeneic bone marrow mesenchymal stromal cells	“OBJECTIVES: To assess the efficacy of a single intradiscal injection of allogeneic bone marrow mesenchymal stromal cells (BM-MSCs) versus a sham placebo in patients with...” PMID 39393844 ↗ Oct 2024
Modality	Cell therapy	“allogeneic cell injection” PMID 39393844 ↗ Oct 2024
Route	Other	“single intradiscal injection of allogeneic bone marrow mesenchymal stromal cells (BM-MSCs)” PMID 39393844 ↗ Oct 2024